John K. Bakewell Joins Corindus Vascular Robotics Board of Directors

8/8/17

John K. Bakewell

WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that John K. Bakewell has been appointed to its board of directors, effective immediately. Mr. Bakewell will serve as the Chair of the Audit Committee.

President and Chief Executive Officer Mark Toland stated, "I am pleased to welcome John to our board of directors. John’s financial expertise coupled with his tremendous experience driving sustainable growth within transformational companies will be invaluable to our organization."

Mr. Bakewell has served in executive capacities for more than two decades, building and executing operational and financial strategies for growing businesses across the healthcare sector. Over the course of his career, he has served as Chief Financial Officer at Exact Sciences Corporation, Lantheus Holdings, Inc., Interline Brands, Inc., Regional Care Hospital Partners, Wright Medical Group, Inc., Altra Energy Technologies, Inc., Cyberonics, Inc., and Zeos International, Ltd. Mr. Bakewell is currently a consultant to the medical technology industry. He serves on the board of directors for both Entellus Medical, Inc. and Keystone Dental, Inc. He previously served on the Board of Directors of ev3 Inc. until its acquisition in 2010. Mr. Bakewell holds a Bachelor of Arts in Accounting from the University of Northern Iowa and is a certified public accountant (inactive).

Mr. Bakewell said, "I am delighted to join Corindus and am committed to its mission of bringing robotic-assisted precision and its many benefits to vascular interventions. I look forward to working with the Corindus team as the company continues to drive adoption of its technology, addressing the significant unmet needs of interventional cardiology."

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.